Look at company value not SP27 Aug 2024 10:23
I am definitely more in the £8 camp than £1.
Although not guaranteed there is very strong evidence that SCIB1 works.
Confirmation of this in 40 patients will be transforming.
Given we did a deal for one preclinical anti body worth up to $625m. Scib1 will get more than this.
Looking at the SP and saying it won't go above £1 because it was at 10p for so long is wrong.
The problem has been how lowly we have been valued not what are worth